Last reviewed · How we verify
Dextrose 5% in water
At a glance
| Generic name | Dextrose 5% in water |
|---|---|
| Also known as | Dextrose 5% in Water (D5W), Dextrose, SCH 056592 (2), Vitagen, D5W |
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (PHASE1, PHASE2)
- The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery (PHASE4)
- Adjunctive Methylene Blue in Septic Shock (PHASE3)
- Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease (EARLY_PHASE1)
- Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers (PHASE1)
- Determination of the Glycemic Index of Products Varying in Levels of Refined and Whole Grain Corn (NA)
- Impact of Bupivacaine Dilution With Dextrose or Saline on Infraclavicular Block Outcomes (NA)
- Safety of Sildenafil in Premature Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dextrose 5% in water CI brief — competitive landscape report
- Dextrose 5% in water updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI